Tags

Type your tag names separated by a space and hit enter

[Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza].
Ned Tijdschr Geneeskd. 2004 Jan 10; 148(2):73-9.NT

Abstract

Recently two new neuraminidase inhibitors zanamivir and oseltamivir have been marketed. They appear to considerably reduce morbidity and mortality from influenza. Their adverse effects are infrequent and mild and the chance of development of pathogenically significant resistant mutants appears to be small. During the first six months of a pandemic, neuraminidase inhibitors are the only defence against the virus. It is therefore important to stockpile in each country sufficient quantities of these drugs. During the usual influenza epidemics the main value of neuraminidase inhibitors lies in their use for therapy, prophylaxis and post-exposure prophylaxis in long-term care institutions for the elderly (for prophylaxis only oseltamivir is licensed). Although data on the effectiveness against complications of influenza and on the effect on people with an increased risk of (fatal) complications as a result of an influenza virus infection are limited, the available information on the effects of the neuraminidinase inhibitors indicates that these drugs will also protect against complications and that high-risk groups will benefit from the rapid deployment of these products. The cost-effectiveness of treatment and post-exposure prophylaxis with neuraminidinase inhibitors is probably not favourable for healthy children and adults but seems to be favourable for the high-risk groups (vaccinated or not) in winter.

Authors+Show Affiliations

Erasmus Medisch Centrum, afd. Virologie, Postbus 1738, 3000 DR Rotterdam. jc.de.jong@wxs.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

14753128

Citation

de Jong, J C., et al. "[Neuraminidase Inhibitors Oseltamivir and Zanamivir: New Means of Defence Against Influenza]." Nederlands Tijdschrift Voor Geneeskunde, vol. 148, no. 2, 2004, pp. 73-9.
de Jong JC, Beyer WE, Rimmelzwaan GF, et al. [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]. Ned Tijdschr Geneeskd. 2004;148(2):73-9.
de Jong, J. C., Beyer, W. E., Rimmelzwaan, G. F., Fouchier, R. A., & Osterhaus, A. D. (2004). [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]. Nederlands Tijdschrift Voor Geneeskunde, 148(2), 73-9.
de Jong JC, et al. [Neuraminidase Inhibitors Oseltamivir and Zanamivir: New Means of Defence Against Influenza]. Ned Tijdschr Geneeskd. 2004 Jan 10;148(2):73-9. PubMed PMID: 14753128.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Neuraminidase inhibitors oseltamivir and zanamivir: new means of defence against influenza]. AU - de Jong,J C, AU - Beyer,W E, AU - Rimmelzwaan,G F, AU - Fouchier,R A, AU - Osterhaus,A D, PY - 2004/2/3/pubmed PY - 2004/4/7/medline PY - 2004/2/3/entrez SP - 73 EP - 9 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 148 IS - 2 N2 - Recently two new neuraminidase inhibitors zanamivir and oseltamivir have been marketed. They appear to considerably reduce morbidity and mortality from influenza. Their adverse effects are infrequent and mild and the chance of development of pathogenically significant resistant mutants appears to be small. During the first six months of a pandemic, neuraminidase inhibitors are the only defence against the virus. It is therefore important to stockpile in each country sufficient quantities of these drugs. During the usual influenza epidemics the main value of neuraminidase inhibitors lies in their use for therapy, prophylaxis and post-exposure prophylaxis in long-term care institutions for the elderly (for prophylaxis only oseltamivir is licensed). Although data on the effectiveness against complications of influenza and on the effect on people with an increased risk of (fatal) complications as a result of an influenza virus infection are limited, the available information on the effects of the neuraminidinase inhibitors indicates that these drugs will also protect against complications and that high-risk groups will benefit from the rapid deployment of these products. The cost-effectiveness of treatment and post-exposure prophylaxis with neuraminidinase inhibitors is probably not favourable for healthy children and adults but seems to be favourable for the high-risk groups (vaccinated or not) in winter. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/14753128/[Neuraminidase_inhibitors_oseltamivir_and_zanamivir:_new_means_of_defence_against_influenza]_ L2 - https://medlineplus.gov/flu.html DB - PRIME DP - Unbound Medicine ER -